Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of usefulness of manual reduction in the management of adult acute irreducible abdominal wall hernia: a study from a community-based teaching hospital.

Hernia : the journal of hernias and abdominal wall surgery·2026

Same author

Analysis of <i>PIK3CA</i> mutations in the lysate of sentinel lymph nodes in patients with early breast cancer.

Frontiers in oncology·2026

Same author

A rare case of mastitis involving granulomatosis with polyangiitis after immune checkpoint inhibitor therapy.

International cancer conference journal·2026

Same author

Roles and Therapeutic Application of Vasohibin-2 in Cancers.

The Tohoku journal of experimental medicine·2026

Same author

[A Case Study of Severe Myelosuppression Induced by Adjuvant Chemotherapy in a Breast Cancer Patient with Concurrent Immune Thrombocytopenia(ITP)].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Same author

[Treatment Outcomes for Six Cases of Gastric Cancer with Brain Metastases].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

[Anti-angiogenic drugs].

Yasufumi Sato¹

¹Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University.

Nihon Rinsho. Japanese Journal of Clinical Medicine

|October 20, 2010

Summary

Anti-angiogenesis treatments, including bevacizumab, target new blood vessel formation crucial for tumor growth and blindness-causing eye diseases. This review details current anti-angiogenesis therapies for cancer and ocular conditions.

Area of Science:

* Physiology and Pathology: Explores the dual role of angiogenesis (neovascularization) in normal vasculature and its pathological involvement in cancers and ocular diseases.
* Pharmacology: Focuses on anti-angiogenic drugs, particularly monoclonal antibodies targeting vascular endothelial growth factor (VEGF).

Context:

* Pathological Angiogenesis: Highlights the critical role of new blood vessel formation in tumor growth, metastasis, and as a primary cause of adult blindness.
* Therapeutic Landmark: Notes the development of bevacizumab in 2004 as the first anti-angiogenic drug, marking a significant advancement.

Purpose:

* Review Current Treatments: To provide an overview of the current status and advancements in anti-angiogenesis therapies.
* Clinical Significance: To underscore the importance of anti-angiogenic drugs in managing cancers and ocular diseases.

Summary:

* Mechanism of Action: Discusses drugs that neutralize VEGF, inhibiting the signaling pathway essential for angiogenesis.

More Related Videos

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Experiment Videos

Last Updated: Jun 8, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

* Therapeutic Applications: Details the use of anti-angiogenic drugs in controlling tumor progression and treating sight-threatening eye conditions.

* Drug Development: Covers the evolution of anti-angiogenic agents beyond bevacizumab for targeted cancer and ocular disease therapy.

Impact:

* Oncology: Anti-angiogenic drugs represent a major therapeutic strategy for controlling cancer growth and metastasis.
* Ophthalmology: These therapies offer new hope for preventing vision loss in angiogenesis-related eye diseases.
* Clinical Practice: Anti-angiogenesis treatments are now a recognized and vital component of modern medical care for specific cancers and ocular conditions.